Prognostic factors for radioimmunotherapy in patients with B-lymphocytic malignancies

Gerald L Denardo, Kathleen R. Lamborn, Sally J. DeNardo, Desirée S. Goldstein, Edward G. Dolber-Smith, Linda A. Kroger, Edward C. Larkin, Sui Shen

Research output: Contribution to journalArticle

18 Citations (Scopus)

Abstract

The Ann Arbor staging classification has proven less useful in non-Hodgkin's lymphoma, because this malignancy is inherently a multifocal disorder. Since 1985, 57 adult patients with advanced B-lymphocytic malignancies that progressed despite standard therapy entered into one of three different therapy trials using radiolabeled Lym-1 antibody. Tumor regression in 31 (54%) of these patients fulfilled conventional requirements for an oncological response to the therapy. To define the role of radioimmunotherapy in B-lymphocytic malignancies better and to find opportunities for improving its therapeutic efficacy, the records of these patients were reviewed to assess the significance of various parameters as prognostic indicators. Twenty-one pretherapy characteristics were evaluated, including age at diagnosis, age at study entry, sex, Karnofsky performance status, prior chemotherapy and radiation therapy, interval since diagnosis, histology, constitutional B symptoms, extranodal malignancy (excluding marrow), bone marrow malignancy, tumor bulk, and circulating malignant cells; blood tests included lymphocyte, granulocyte, platelet, hematocrit, serum lactate dehydrogenase (LDH), interleukin 2 receptor, and human antimouse antibody levels. In the multivariate analysis, LDH and Karnofsky performance status were the parameters that best predicted survival, complete and partial remission, and time to progression; interleukin 2 receptor and LDH best predicted complete remission. These prognostic factors for radioimmunotherapy outcome are consistent with the pretherapy characteristics observed to be significant for chemotherapy.

Original languageEnglish (US)
JournalCancer Research
Volume55
Issue number23 SUPPL.
StatePublished - 1995

Fingerprint

Radioimmunotherapy
Neoplasms
Karnofsky Performance Status
Interleukin-2 Receptors
L-Lactate Dehydrogenase
Bone Marrow
Drug Therapy
Antibodies
Hematologic Tests
Therapeutics
Hematocrit
Granulocytes
Non-Hodgkin's Lymphoma
Histology
Radiotherapy
Blood Platelets
Multivariate Analysis
Lymphocytes
Survival
Serum

ASJC Scopus subject areas

  • Cancer Research
  • Oncology

Cite this

Denardo, G. L., Lamborn, K. R., DeNardo, S. J., Goldstein, D. S., Dolber-Smith, E. G., Kroger, L. A., ... Shen, S. (1995). Prognostic factors for radioimmunotherapy in patients with B-lymphocytic malignancies. Cancer Research, 55(23 SUPPL.).

Prognostic factors for radioimmunotherapy in patients with B-lymphocytic malignancies. / Denardo, Gerald L; Lamborn, Kathleen R.; DeNardo, Sally J.; Goldstein, Desirée S.; Dolber-Smith, Edward G.; Kroger, Linda A.; Larkin, Edward C.; Shen, Sui.

In: Cancer Research, Vol. 55, No. 23 SUPPL., 1995.

Research output: Contribution to journalArticle

Denardo, GL, Lamborn, KR, DeNardo, SJ, Goldstein, DS, Dolber-Smith, EG, Kroger, LA, Larkin, EC & Shen, S 1995, 'Prognostic factors for radioimmunotherapy in patients with B-lymphocytic malignancies', Cancer Research, vol. 55, no. 23 SUPPL..
Denardo GL, Lamborn KR, DeNardo SJ, Goldstein DS, Dolber-Smith EG, Kroger LA et al. Prognostic factors for radioimmunotherapy in patients with B-lymphocytic malignancies. Cancer Research. 1995;55(23 SUPPL.).
Denardo, Gerald L ; Lamborn, Kathleen R. ; DeNardo, Sally J. ; Goldstein, Desirée S. ; Dolber-Smith, Edward G. ; Kroger, Linda A. ; Larkin, Edward C. ; Shen, Sui. / Prognostic factors for radioimmunotherapy in patients with B-lymphocytic malignancies. In: Cancer Research. 1995 ; Vol. 55, No. 23 SUPPL.
@article{10d187b0864c4dbca1b3ee63e7e2310c,
title = "Prognostic factors for radioimmunotherapy in patients with B-lymphocytic malignancies",
abstract = "The Ann Arbor staging classification has proven less useful in non-Hodgkin's lymphoma, because this malignancy is inherently a multifocal disorder. Since 1985, 57 adult patients with advanced B-lymphocytic malignancies that progressed despite standard therapy entered into one of three different therapy trials using radiolabeled Lym-1 antibody. Tumor regression in 31 (54{\%}) of these patients fulfilled conventional requirements for an oncological response to the therapy. To define the role of radioimmunotherapy in B-lymphocytic malignancies better and to find opportunities for improving its therapeutic efficacy, the records of these patients were reviewed to assess the significance of various parameters as prognostic indicators. Twenty-one pretherapy characteristics were evaluated, including age at diagnosis, age at study entry, sex, Karnofsky performance status, prior chemotherapy and radiation therapy, interval since diagnosis, histology, constitutional B symptoms, extranodal malignancy (excluding marrow), bone marrow malignancy, tumor bulk, and circulating malignant cells; blood tests included lymphocyte, granulocyte, platelet, hematocrit, serum lactate dehydrogenase (LDH), interleukin 2 receptor, and human antimouse antibody levels. In the multivariate analysis, LDH and Karnofsky performance status were the parameters that best predicted survival, complete and partial remission, and time to progression; interleukin 2 receptor and LDH best predicted complete remission. These prognostic factors for radioimmunotherapy outcome are consistent with the pretherapy characteristics observed to be significant for chemotherapy.",
author = "Denardo, {Gerald L} and Lamborn, {Kathleen R.} and DeNardo, {Sally J.} and Goldstein, {Desir{\'e}e S.} and Dolber-Smith, {Edward G.} and Kroger, {Linda A.} and Larkin, {Edward C.} and Sui Shen",
year = "1995",
language = "English (US)",
volume = "55",
journal = "Journal of Cancer Research",
issn = "0099-7013",
publisher = "American Association for Cancer Research Inc.",
number = "23 SUPPL.",

}

TY - JOUR

T1 - Prognostic factors for radioimmunotherapy in patients with B-lymphocytic malignancies

AU - Denardo, Gerald L

AU - Lamborn, Kathleen R.

AU - DeNardo, Sally J.

AU - Goldstein, Desirée S.

AU - Dolber-Smith, Edward G.

AU - Kroger, Linda A.

AU - Larkin, Edward C.

AU - Shen, Sui

PY - 1995

Y1 - 1995

N2 - The Ann Arbor staging classification has proven less useful in non-Hodgkin's lymphoma, because this malignancy is inherently a multifocal disorder. Since 1985, 57 adult patients with advanced B-lymphocytic malignancies that progressed despite standard therapy entered into one of three different therapy trials using radiolabeled Lym-1 antibody. Tumor regression in 31 (54%) of these patients fulfilled conventional requirements for an oncological response to the therapy. To define the role of radioimmunotherapy in B-lymphocytic malignancies better and to find opportunities for improving its therapeutic efficacy, the records of these patients were reviewed to assess the significance of various parameters as prognostic indicators. Twenty-one pretherapy characteristics were evaluated, including age at diagnosis, age at study entry, sex, Karnofsky performance status, prior chemotherapy and radiation therapy, interval since diagnosis, histology, constitutional B symptoms, extranodal malignancy (excluding marrow), bone marrow malignancy, tumor bulk, and circulating malignant cells; blood tests included lymphocyte, granulocyte, platelet, hematocrit, serum lactate dehydrogenase (LDH), interleukin 2 receptor, and human antimouse antibody levels. In the multivariate analysis, LDH and Karnofsky performance status were the parameters that best predicted survival, complete and partial remission, and time to progression; interleukin 2 receptor and LDH best predicted complete remission. These prognostic factors for radioimmunotherapy outcome are consistent with the pretherapy characteristics observed to be significant for chemotherapy.

AB - The Ann Arbor staging classification has proven less useful in non-Hodgkin's lymphoma, because this malignancy is inherently a multifocal disorder. Since 1985, 57 adult patients with advanced B-lymphocytic malignancies that progressed despite standard therapy entered into one of three different therapy trials using radiolabeled Lym-1 antibody. Tumor regression in 31 (54%) of these patients fulfilled conventional requirements for an oncological response to the therapy. To define the role of radioimmunotherapy in B-lymphocytic malignancies better and to find opportunities for improving its therapeutic efficacy, the records of these patients were reviewed to assess the significance of various parameters as prognostic indicators. Twenty-one pretherapy characteristics were evaluated, including age at diagnosis, age at study entry, sex, Karnofsky performance status, prior chemotherapy and radiation therapy, interval since diagnosis, histology, constitutional B symptoms, extranodal malignancy (excluding marrow), bone marrow malignancy, tumor bulk, and circulating malignant cells; blood tests included lymphocyte, granulocyte, platelet, hematocrit, serum lactate dehydrogenase (LDH), interleukin 2 receptor, and human antimouse antibody levels. In the multivariate analysis, LDH and Karnofsky performance status were the parameters that best predicted survival, complete and partial remission, and time to progression; interleukin 2 receptor and LDH best predicted complete remission. These prognostic factors for radioimmunotherapy outcome are consistent with the pretherapy characteristics observed to be significant for chemotherapy.

UR - http://www.scopus.com/inward/record.url?scp=0028843780&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0028843780&partnerID=8YFLogxK

M3 - Article

C2 - 7493366

AN - SCOPUS:0028843780

VL - 55

JO - Journal of Cancer Research

JF - Journal of Cancer Research

SN - 0099-7013

IS - 23 SUPPL.

ER -